These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 31594208)

  • 21. The prognostic value of p53 in superficially infiltrating transitional cell carcinoma.
    Vatne V; Maartmann-Moe H; Hoestmark J
    Scand J Urol Nephrol; 1995 Dec; 29(4):491-5. PubMed ID: 8719368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Karnofsky performance status predicts overall survival, cancer-specific survival, and progression-free survival following radical cystectomy for urothelial carcinoma.
    Evers PD; Logan JE; Sills V; Chin AI
    World J Urol; 2014 Apr; 32(2):385-91. PubMed ID: 23756991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. D2-40/podoplanin expression in cancer stroma by immunohistochemical staining is associated with poor prognosis in bladder cancer patients after radical cystectomy.
    Okajima E; Tomizawa M; Shimada K; Negishi T; Nishiyama N; Kitamura H
    Urol Oncol; 2020 Oct; 38(10):797.e7-797.e13. PubMed ID: 32576528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.
    Minato A; Noguchi H; Tomisaki I; Fukuda A; Kubo T; Nakayama T; Fujimoto N
    Cancer Control; 2018; 25(1):1073274818800269. PubMed ID: 30213195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma.
    Rodríguez-Alonso A; Pita-Fernández S; González-Carreró J; Nogueira-March JL
    Eur Urol; 2002 Feb; 41(2):182-8; discussion 188-9. PubMed ID: 12074407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer.
    Kelloniemi E; Rintala E; Finne P; Stenman UH;
    Urology; 2003 Aug; 62(2):249-53. PubMed ID: 12893328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a.
    May M; Bastian PJ; Brookman-May S; Fritsche HM; Tilki D; Otto W; Bolenz C; Gilfrich C; Trojan L; Herrmann E; Moritz R; Tiemann A; Müller SC; Ellinger J; Buchner A; Stief CG; Wieland WF; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Nuhn P; Burger M
    Urol Oncol; 2013 Oct; 31(7):1141-7. PubMed ID: 22056404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy.
    Wu CS; Pollack A; Czerniak B; Chyle V; Zagars GK; Dinney CP; Hu SX; Benedict WF
    Urology; 1996 Mar; 47(3):305-10. PubMed ID: 8633392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dramatic impact of blood transfusion on cancer-specific survival after radical cystectomy irrespective of tumor stage.
    Buchner A; Grimm T; Schneevoigt BS; Wittmann G; Kretschmer A; Jokisch F; Grabbert M; Apfelbeck M; Schulz G; Gratzke C; Stief CG; Karl A
    Scand J Urol; 2017 Apr; 51(2):130-136. PubMed ID: 28332428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 overexpression as a prognostic factor for advanced stage bladder cancer.
    Kuczyk MA; Bokemeyer C; Serth J; Hervatin C; Oelke M; Höfner K; Tan HK; Jonas U
    Eur J Cancer; 1995 Dec; 31A(13-14):2243-7. PubMed ID: 8652250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy.
    Kolla SB; Seth A; Singh MK; Gupta NP; Hemal AK; Dogra PN; Kumar R
    Int Urol Nephrol; 2008; 40(2):321-7. PubMed ID: 17899426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients.
    Gaber A; Nodin B; Hotakainen K; Nilsson E; Stenman UH; Bjartell A; Birgisson H; Jirström K
    BMC Cancer; 2010 Sep; 10():498. PubMed ID: 20849596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3).
    Bongiovanni L; Arena V; Vecchio FM; Racioppi M; Bassi P; Pierconti F
    Arch Ital Urol Androl; 2013 Jun; 85(2):73-7. PubMed ID: 23820653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
    Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.
    Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF
    Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. External validation of extranodal extension and lymph node density as predictors of survival in node-positive bladder cancer after radical cystectomy.
    Masson-Lecomte A; Vordos D; Hoznek A; Yiou R; Allory Y; Abbou CC; de la Taille A; Salomon L
    Ann Surg Oncol; 2013 Apr; 20(4):1389-94. PubMed ID: 23208127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.